What You Need to Know Ahead of Thermo Fisher Scientific's Earnings Release

Core Viewpoint - Thermo Fisher Scientific Inc. (TMO) is a leading provider of life sciences solutions and is expected to announce its fiscal first-quarter earnings for 2026 soon, with analysts projecting a profit increase [1][2]. Financial Performance - Analysts anticipate TMO will report a diluted EPS of $5.31 for Q1 2026, reflecting a 3.1% increase from $5.15 in the same quarter last year [2]. - For the full fiscal year 2026, TMO's EPS is expected to reach $24.66, marking a 7.8% increase from $22.87 in fiscal 2025, with further growth projected to $27 in fiscal 2027, a 9.5% year-over-year rise [3]. Earnings History - TMO has consistently exceeded Wall Street's EPS estimates in its last four quarterly reports, with reported EPS figures surpassing estimates by margins ranging from 0.98% to 5.27% [4][5]. - The company's Q4 results showed an adjusted EPS of $6.57, exceeding expectations of $6.43, with revenue reported at $12.2 billion, above the forecast of $11.9 billion [5]. Analyst Ratings - The consensus among analysts is bullish, with a "Strong Buy" rating for TMO stock. Out of 23 analysts, 18 recommend a "Strong Buy," while two suggest a "Moderate Buy" and three a "Hold" [6]. - The average analyst price target for TMO is $665.28, indicating a potential upside of 36.1% from current levels [6]. Stock Performance - TMO stock has underperformed the S&P 500 Index, which gained 13.4% over the past 52 weeks, with TMO shares down 4.8% during the same period [4].